Company Encyclopedia
View More
name
PEIJIA-B
09996.HK
Peijia Medical Limited, together with its subsidiaries, engages in the research, development, manufacturing, and sales of transcatheter valve therapeutic and neurointerventional procedural medical devices in the People’s Republic of China. It operates through Transcatheter Valve Therapeutic Business, Neurointerventional Business, and Future Technology Business segments. The company products include transcatheter aortic valve replacement (TAVR) systems, crosslinked dry-tissue and polymeric tri leaflet TAVR systems, transcatheter aortic valve systems, transseptal mitral valve replacement systems, transfemoral balloon catheter, introducer sheath, pre-shaped guidewire, detachable coils, balloon guide catheter, aspiration catheter, stent retriever, delivery balloon dilatation catheter, balloon dilatation catheter, microcatheter, micro guidewire, micro guidewire, guide catheter, distal access guide catheter, intermediate catheter, and power supply. In addition, it engages in the trading and holding business.
133.60 B
09996.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking16/26
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-10.85%D
    • Profit Margin-33.73%E
    • Gross Margin70.07%A
  • Growth ScoreB
    • Revenue YoY29.22%A
    • Net Profit YoY10.41%C
    • Total Assets YoY1.35%C
    • Net Assets YoY-7.25%D
  • Cash ScoreC
    • Cash Flow Margin-296.50%D
    • OCF YoY29.22%A
  • Operating ScoreD
    • Turnover0.26D
  • Debt ScoreB
    • Gearing Ratio23.63%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Morning Trend | PEIJIA-B experiences a decline on low volume, will sudden news amplify momentum?

    Peijia Medical (9996.HK) maintained a low-volume downward trend throughout the day on October 30, with funds generally adopting a wait-and-see approach in the innovative drug and medical device segments. Mainstream incremental capital has not entered the market, and the stock price is operating at the lower end of the consolidation range, forming a downward momentum technically. The company has recently lacked positive disclosures regarding R&D or industrial implementation, and there has been no strong catalyst for the innovative drug market recently, with market evaluations remaining conservative. On the technical side, trading volume continues to be sluggish, and right-side incremental capital has yet to be activated. Some investors and analysts are focusing on foreign capital pharmaceutical ETFs and liquidity signals in Hong Kong's pharmaceutical sector, hoping to form a new trend guidance. Short-term strategies remain primarily defensive with low positions. If there are intraday capital fluctuations or key industry news resonances, it may become a turning point for a rebound. Before that, it is advisable to wait patiently and avoid blindly increasing positions at high prices. In the future, changes in policies or external news may suddenly amplify momentum, potentially bringing about short-term opportunities, but caution should be exercised against sudden negative news

    Technical Forecast·
    HK
    09996
    +0.73%
    Technical Forecast·
    HK
    09996
    +0.73%

    Morning Trend | PEIJIA Medical steps down, funds are on the sidelines, when will the new wave of hotspots start?

    PEIJIA Medical -B (9996.HK) has recently experienced a downward trend after an initial surge, with market sentiment continuing to weaken and new capital entering still on the sidelines. Major funds have reduced their holdings from high positions, and the willingness of retail investors to engage in short-term speculation is low. The technical indicators are consistently declining, with the K-line arrangement showing characteristics of a bearish pattern. Trading volume is shrinking daily, and the market's cautious sentiment indicates that it is still waiting for new speculative logic or industry hotspots. The medical device sector is generally weak, and without significant catalysts or strong support, the stock may struggle to escape its sluggish state in the short term. Community traders are mostly waiting for bottom signals, while some active funds are focusing on new trading themes in the innovative medical field, but without new drivers, proactive engagement is unlikely. Although there is a high probability of continued downward movement within the range, any intraday fluctuations or significant industry news could trigger a rebound from oversold conditions at any time. From an operational perspective, it is advisable to maintain a light position and observe before following the right-side trend after a stabilization in volume. If it continues to break below previous lows, timely stop-loss measures should be taken. During periods of low capital sentiment, it is important to avoid passive entrapment from left-side bottom fishing and to pay attention to volume fluctuations and industry changes to capture early opportunities. For those seeking short-term opportunities, PEIJIA Medical is currently in a downward continuation phase, with the main trend still unclear. A true trading frenzy will only arrive with a switch in hotspots and new major movements

    Technical Forecast·
    HK
    09996
    +0.73%
    Technical Forecast·
    HK
    09996
    +0.73%

    PEIJIA-B: The National Medical Products Administration has accepted the registration application for the GeminiOne® Transcatheter Edge-to-Edge Repair System

    PEIJIA-B announced that it has received a confirmation letter from the National Medical Products Administration of China, confirming that its registration application for the GeminiOne® transcatheter edge-to-edge repair system has been accepted. This system is an innovative TEER device independently developed by the company, featuring a unique groove-type mechanical structure that allows for a longer grasping arm length while maintaining a small size, and is designed to reduce surgical complexity and adapt to various anatomical structures

    Zhitong·
    HK
    09996
    +0.73%
    Zhitong·
    HK
    09996
    +0.73%

    Peijia Medical GeminiOne TEER System Registration Application Accepted by NMPA

    Peijia Medical Limited announced that the National Medical Products Administration (NMPA) of China has accepted its registration application for the GeminiOne® Transcatheter Edge-to-Edge Repair (TEER) System. This device features a unique sliding groove mechanism and aims to reduce procedural complexity. However, the company cautions that acceptance does not guarantee final approval or successful marketing of the product.

    Reuters·
    HK
    09996
    +0.73%
    Reuters·
    HK
    09996
    +0.73%

    Peijia Medical's TAVR system completes first patient enrollment

    PEIJIA-B announced that the company has enrolled the first patient for the ReachTactile robot-assisted transcatheter aortic valve replacement (TAVR) system. The registered clinical trial for this system is a prospective, multicenter, randomized controlled, non-inferiority study aimed at evaluating the safety and efficacy of the ReachTactile robot-assisted TAVR system and its disposable surgical kit in TAVR procedures

    AASTOCKS·
    HK
    09996
    +0.73%
    AASTOCKS·
    HK
    09996
    +0.73%
    © 2025 Longbridge｜Disclaimer